Mohammad AskarPublic working copy · medical review pending

Infectious uveitis · 169

Infectious uveitis: phenotype, tests and urgent treatment

Localise inflammation and assess immune status before selecting tests and treatment. Infection and a quiet-looking eye can coexist.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Serology or PCR must answer a clinical question. Necrotising retinitis needs urgent antimicrobial care; avoid unopposed steroid escalation.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Choose a clinical question before a test panel

History, geography/exposure, immune status and the ocular phenotype guide diagnosis. Tuberculosis (TB) and syphilis can mimic many uveitis patterns; infectious frequency in the Middle East is context-dependent, not an individual diagnosis. An indiscriminate “full workup” risks false positives, but calling it universal malpractice is an unsupported legal claim. 1

02Recognise toxoplasmic retinochoroiditis

A focal white necrotising lesion next to a pigmented scar with dense overlying vitritis gives the “headlight in fog” appearance, as in the original 56-year-old woman. The original 15-year-old boy has disc swelling and a macular star with a focal lesion: consider toxoplasmosis and Bartonella/cat-scratch neuroretinitis rather than declaring either image pathognomonic. 1

Juxtapapillary disease threatens the nerve; granulomatous anterior activity with mutton-fat precipitates and high IOP may reflect trabeculitis. Immunosuppression can produce multifocal/peripheral aggressive lesions. Kyrieleis segmental arterial plaques support a pattern but are not a unique pathogen test. 1

FA may show early hypofluorescent blockage and late rim staining/leakage; OCT depicts full-thickness retinal injury and EDI may show underlying choroidal thickening. Positive IgG indicates prior exposure, not proof of active ocular causation. Negative serology makes the diagnosis less likely but is not absolute exclusion in early infection or immune impairment. 1

Aqueous/vitreous PCR and intraocular antibody production, assessed with the Goldmann–Witmer coefficient, can complement the clinical diagnosis in selected atypical cases. The export’s PCR 60% and coefficient 50% sensitivities and “rarely used” claim lack protocol/population context; sampling time, immune status and prior therapy matter. 1

03Select toxoplasmosis treatment and monitor safety

Macular/nerve-threatening lesions, dense visually significant vitritis or immunosuppression favour treatment; some small peripheral disease in immunocompetent people may be observed with follow-up. The original 3–6 weeks and co-trimoxazole 960 mg twice daily plus clindamycin 300 mg four times daily are attributed regimen examples, not a universal combined first-line protocol. Check allergies, blood counts, renal function, interactions and specialist advice. 1

Pyrimethamine/sulfadiazine regimens require folinic-acid protection and laboratory monitoring. Pregnancy is not a blanket indication for “safe spiramycin or azithromycin”: gestational timing, maternal ocular disease and fetal infection are separate questions for obstetric/infectious-disease specialists. Systemic steroids, when indicated, need effective anti-parasitic coverage; the original 24–48/48-hour rule is not a precisely validated deadline for all regimens. 1

A randomised trial compared 1–3 intravitreal injections of clindamycin 1 mg/dexamethasone 400 µg with 6-week systemic pyrimethamine/sulfadiazine/prednisolone. It supports a selected local alternative, not a fixed weekly 2–3-dose rule or universal pregnancy safety; full methods and rare-harm precision remain unappraised. Local steroid with active antimicrobial is distinct from unopposed steroid injection. 1 5

04Assess ocular tuberculosis as a composite diagnosis

Ocular TB may occur without active pulmonary disease or a known history. Granulomatous anterior uveitis with iris nodules, serpiginous-like or multifocal choroiditis/tubercles, a subretinal abscess or occlusive peripheral periphlebitis are compatible patterns; none alone proves TB rather than sarcoidosis or another cause. 1

TST/PPD and IGRA/QuantiFERON identify immune sensitisation, not ocular causation or a reliable exclusion when negative. Combine phenotype, epidemiology, chest imaging and selected sampling with the TB team; using both tests is not obligatory in every case. ICGA can reveal otherwise occult choroidal spots, but does not make every spot a tuberculous granuloma. 1 4

TB-associated serpiginous-like disease may be multifocal and inflammatory; unilateral, macular-sparing and better-prognosis claims are not exclusion rules. The original preserved-choriocapillaris versus melanoma OCT distinction is unvalidated as a standalone test: a choroidal mass still needs multimodal/oncology assessment. 1

BTS recommends standard multidrug ATT for at least 6 months, considering 9–12 months in severe/slow response; the export’s 2-month RIPE then 7–10 months is one source schedule, not universal. Coordinate isoniazid/rifampicin/pyrazinamide/ethambutol safety and optic-neuropathy monitoring. In ischaemic vasculitis, treat infection/inflammation and assess neovascularisation; not every nonperfused area mandates immediate PRP or anti-VEGF-first treatment. Anti-VEGF suppresses new vessels temporarily rather than curing infection or restoring perfusion. 1 4

05Recognise syphilis and use the correct neurological pathway

Acute syphilitic posterior placoid chorioretinopathy (ASPPC) may appear yellow at the posterior pole with ellipsoid-zone disruption and RPE bumps on OCT. Frosted-branch angiitis, necrotising retinitis mimicking ARN, iris roseola and palm/sole rash are other clues, not obligatory signs. Use appropriate treponemal/nontreponemal testing and assess HIV with infectious-disease care. 1

Treat ocular syphilis as neurosyphilis even with normal CSF, rather than claiming every ocular case proves CNS involvement. CDC recommends penicillin G IV for 10–14 days. Neurological/cranial-nerve dysfunction requires CSF evaluation; confirmed isolated ocular disease without those findings does not routinely need lumbar puncture before treatment. Ceftriaxone is a limited-evidence specialist alternative; adjunctive steroids lack proven benefit, so no universal 24–48-hour steroid rule follows. 1 2

06Treat necrotising viral retinitis urgently

ARN combines peripheral necrotising retinitis, circumferential spread and occlusive arteritis, often with anterior/vitreous inflammation. HSV/VZV and immune status matter; immune competence is not a required diagnostic condition. Retinal detachment is an important complication; the original “up to 75%” is a cohort-dependent maximum, not an individual prediction. 1

Obtain appropriate ocular PCR without delaying treatment. The AAO report included 33 retrospective studies; it supports initial systemic oral or IV antivirals and possible adjunct intravitreal foscarnet, not a universal IV-only regimen. The original aciclovir 10 mg/kg three times daily is a source example requiring renal/dose monitoring. ARN urgency resembles endophthalmitis, but the drug pathway is antiviral, not automatically the same antibacterial protocol. Avoid unopposed intraocular/systemic steroids; the original 48-hour start is not universal. 1 6

PORN typically occurs with profound immune impairment, often CD4 <50 cells/µL, with rapid outer-retinal necrosis, posterior/macular involvement and little inflammation; CMV can also look quiet. Neither absence of vitritis nor a “pizza/ketchup” haemorrhagic appearance is obligatory. PORN needs urgent specialist systemic/intravitreal antiviral selection and immune care, not automatic substitution of valganciclovir for every VZV case. 1

CMV retinitis in HIV requires direct anti-CMV treatment plus ART/immune management, not ART alone. Systemic valganciclovir or IV ganciclovir is selected by circumstances, with intravitreal treatment added for immediately sight-threatening lesions. Stopping maintenance requires inactive lesions, at least 3 months of anti-CMV therapy and CD4 ≥100 for at least 3 months on ART with ophthalmic agreement; continue relapse/IRU surveillance. These HIV criteria do not automatically apply to transplant recipients. 1 3

Treat necrotising viral retinitis urgently
FeaturePORNCMV retinitis
PathogenUsually VZVCMV
ContextProfound immune impairment, often CD4 <50; transplantation possibleOften HIV CD4 <50, other immune impairment possible
InflammationOften minimal despite rapid necrosisOften little vitritis; IRU changes the picture
SpreadOften posterior, rapid and bilateralGranular/haemorrhagic advancing lesions, often along vessels
PrognosisOften poor; urgent care still mattersDepends on location, treatment and immune recovery, not guaranteed good
TreatmentSpecialist systemic/intravitreal antivirals matched to pathogenSystemic anti-CMV plus selected intravitreal treatment and immune care

07Distinguish viral anterior phenotypes

HSV/VZV anterior uveitis may show high IOP, granulomatous precipitates, reduced corneal sensation and sectoral iris atrophy; none alone identifies the virus. CMV can produce recurrent pressure spikes with little inflammation and few synechiae, but Posner–Schlossman is not synonymous with proven CMV, and the export’s 100% recurrence without antiviral is unverified. Selected aqueous PCR may change treatment. 1

For confirmed CMV anterior disease, oral valganciclovir or topical ganciclovir are specialist options with toxicity, formulation, local-label and recurrence limits; pressure/anti-inflammatory care is not automatically forbidden. Fuchs syndrome has a characteristic chronic phenotype, often little redness and no posterior synechiae, but steroid nonresponse or normal corneal sensation alone does not diagnose it; cataract/glaucoma still need follow-up. 1

Distinguish viral anterior phenotypes
DiseaseContextKey patternDiagnostic approachTreatment boundary
ToxoplasmosisImmune competent or impairedFocal retinochoroiditis, scar, vitritisClinical plus selected ocular testsSelected antiparasitic regimen; no universal co-trimoxazole/clindamycin combination
Ocular TBExposure/epidemiology and phenotypeSerpiginous-like choroiditis, occlusive periphlebitisComposite; positive IGRA alone is insufficientATT ≥6 months, consider 9–12 when indicated; monitor toxicity
Ocular syphilisAny compatible atypical patternASPPC/retinitis/vasculitis, possible rashSerology, ocular/neurological examinationIV penicillin as neurosyphilis; LP according to neurological findings
ARNOften immune competent, not exclusivelyPeripheral necrosis, occlusive arteritisClinical with ocular PCR; no treatment delaySystemic oral/IV antiviral, selected intravitreal adjunct
CMV retinitisOften profound immune impairmentNecrotising lesions ±haemorrhage, little vitritisExpert dilated assessment, selected PCRAnti-CMV and immune care; maintenance stopping requires all criteria
What are the main learning points?

Serology or PCR must answer a clinical question. Necrotising retinitis needs urgent antimicrobial care; avoid unopposed steroid escalation.

When is assessment urgent?

New rapid visual loss, retinal whitening/necrosis, severe pain or suspected infection during immunosuppression needs urgent specialist assessment; sampling must not create a harmful delay.

References and access status

  1. 1
    Immutable original export; infectious uveitis lecture

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    CDC ocular/neurosyphilis treatment guidance

    Full short page read 15 November 2026; linked evidence and local labels unread.

  3. 3
    NIH HIV CMV disease, 2025 update / 2026 review

    Selected CMV retinitis manifestations/diagnosis and treatment/stop-maintenance sections read 15 November 2026; not every systemic section or underlying trial.

  4. 4
    BTS ocular TB clinical statement 2022

    Selected actual indexed diagnostic/IGRA/TST and treatment-duration text read 15 November 2026; not whole statement or every study.

  5. 5
    Soheilian et al. randomised IV clindamycin/dexamethasone trial

    Selected indexed original design/regimen text read 15 November 2026; complete report/outcome tables/supplements unread.

  6. 6
    AAO ARN evidence report 2017

    Complete PubMed abstract read 15 November 2026:33 retrospective studies; full report/supplements unread.

Original lecture link